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In human medicine there have been many studies reporting the
importance of evaluating serum ET-1 or big ET-1 in various diseases
as a clinical marker, especially related to pulmonary hypertension
and several tumors. In veterinary medicine, however, few studies
have been performed on the clinical importance of serum ET-1 or
big ET-1. In this study we explored the feasibility of using the serum
big ET-1 as a clinical marker in dogs with various cardiopulmonary
and neoplastic diseases. Pulmonary hypertension was diagnosed in
dogs by echocardiography based on the velocity of tricuspid valve
regurgitation. Serum big ET-1 and NT-pro BNP concentrations in these
dogsweremeasuredby ELISA and comparedwith those of healthy dogs.
Serum big ET-1 concentration in dogs with various neoplastic diseases
was also assessed and compared. Our results showed a signiﬁcant
increase of serum big ET-1 in dogs with pulmonary hypertension,
lung tumor and hemangiosarcoma when compared to normal dogs.
No signiﬁcant difference was observed in NT-pro BNP concentration
between healthy and pulmonary hypertension dogs. Although further
studies are necessary, these ﬁndings point to the potential of serum big
ET-1 as a clinical marker in canine pulmonary hypertension and for
some tumor types.
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A 56-year-old man developed sudden dyspnoea after resection of
choroidal melanoma in his left eyeball. Worsening hypoxia required
intensive treatment, including percutaneous cardiopulmonary support.
On contrast-enhanced computed tomography there was no evidence
of either thrombi in the pulmonary arteries or obvious lung diseases.
A Swan–Ganz catheter showed increased mean pulmonary arterial
pressure and no elevation of pulmonary capillary wedge pressure.
These ﬁndings were consistent with a diagnosis of pulmonary arterial
hypertension. Because reports have described a signiﬁcant relation-
ship between melanoma and endothelin (ET)-1, we hypothesized that
a substantial amount of ET-1 had been released from malignant mela-
noma cells during resection, thus triggering the pulmonary hyperten-
sive crisis in our patient. The patient fully recovered after intensive
treatment and administration of the endothelin receptor antagonist
bosentan. The success of bosentan treatment, along with an extremely
high level of ET-1 on pathologic analysis, conﬁrmed our hypothesis
regarding an increase in plasma ET-1 level — 9.60 pg/mL (normal
range b 2.3 pg/mL).
doi:10.1016/j.lfs.2013.12.051
Pharmacokinetics of SPI-1620 in a Phase I, open label, ascending
dose study of the safety, tolerability, pharmacokinetics and
pharmacodynamics of the endothelin B receptor agonist,
SPI-1620, in recurrent or progressive carcinoma
Guru Reddya, Anthony Tolcherb, Anil Gulatic,
Shanta Chawlaa, Lee F. Allena
aSpectrum Pharmaceuticals, Irvine, CA, USA
bSouth Texas Accelerated Research Therapeutics, San Antonio, TX, USA
cMidwestern University, Downers Grove, IL, USA
E-mail address: guru.reddy@sppirx.com (G. Reddy)
Objective: The primary objective of the Phase I study was to assess
the safety and tolerability of SPI-1620 administered to patients with
recurrent or progressive carcinomawhohad failed all standard therapy.
Secondary objectives were to assess PK and PD proﬁles of SPI-1620,
and to identify the optimum dose of SPI-1620 to be used in future
Phase II studies. The pharmacokinetic properties of SPI-1620 will be
presented. Methods: Eligible patients received SPI-1620 by intravenous
infusion over 1 min in an accelerated dose escalation scheme. SPI-1620
doses ranged from 0.5 μg/m2 to 15.1 μg/m2. Serial blood samples were
collected from each patient prior to infusion (0 min) and at pre-
speciﬁed intervals from the start of the infusion. Human plasma
samples were analyzed by a validated HPLC–MS/MS method. Descrip-
tive PK parameters were determined by standard model independent
methods based on the concentration–time data of each subject. Results
& conclusion: The highest concentration of SPI-1620 was achieved
by the end of infusion. SPI-1620 C max increased proportionally as a
function of SPI-1620 dosewhile the AUC (0–T) increased in amore than
dose proportional manner. The SPI-1620 T 1/2 was short and ranged
from 4.38 min to 8.29 min. SPI-1620 had a low systemic clearance and
small VD (approximately equal to the intravascular volume).
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The epithelial–mesenchymal transition (EMT) is known to play a
crucial role in the aggressiveness of epithelial ovarian cancer (EOC),
contributing to chemoresistance and cancer stem cell populations. In
this tumor, the endothelin (ET)-1/endothelin A receptor (ETAR) axis,
by regulating EMT and invasion, endows EOC cells with an increased
chemoresistance. Here we examined whether β-arrestin-1 (β-arr1)
can act as a nuclear hub orchestrating nuclear signaling in ETAR-
driven EMT and chemoresistance. A signiﬁcant higher expression of
β-arr1 and ET-1/ETAR and the stronger presence of β-arr1 in the
nuclear compartment upon ETAR activation are present in chemo-
resistant cells, compared to sensitive cells. In the nuclei, β-arr1
robustly interacts with β-catenin to form a nuclear complex localized
on the ET-1 promoter region, leading to transcription of ET-1, dem-
onstrating that β-arr1 drives the positive inter-regulation of ET-1
itself. This autocrine circuit is involved in β-arr1-driven appearance
of EMT features and acquisition of stem-cell like properties. More-
over, at functional level, chemoresistant cells, with high nuclear
β-arr1, display higher invasive potential and increased resistance
to chemotherapeutic drugs. These effects were inhibited by ET-1
receptor blockade with macitentan, or by β-arr1 nuclear mutant.
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